Prediction of response to imatinib in patients with chronic myelogenous leukemia by flow cytometric analysis of bone marrow blastic cell phenotypes-Reference-Cited by-同舟云学术

Prediction of response to imatinib in patients with chronic myelogenous leukemia by flow cytometric analysis of bone marrow blastic cell phenotypes

Published:2009-01 Issue:2 Volume:50 Page:290-293
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Oka Satoko,Muroi Kazuo,Mori Masaki,Matsuyama Tomohiro,Fujiwara Shin-Ichiro,Oh Iekuni,Sato Kazuya,Kikuchi Satoru,Ueda Masuzu,Toshima Masaki,Suzuki Takahiro,Ozaki Katsutoshi,Nagai Tadashi,Ozawa Keiya

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.1080/10428190802627598

Reference15 articles.

1. Chronic Myeloid Leukemia Stem Cells

2. Imatinib Mesylate — A New Oral Targeted Therapy

3. Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

4. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

5. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronic Myeloid Leukemia, from Pathophysiology to Treatment-Free Remission: A Narrative Literature Review;Journal of Blood Medicine;2023-04

2. Prediction of Progression from Refractory Cytopenia with Unilineage Dysplasia by Analysis of Bone Marrow Blast Cell Composition;Journal of Clinical and Experimental Hematopathology;2012

3. Diseases;Flow Cytometry of Hematological Malignancies;2011-06-27